NCT07491094 Repeated Examinations for Typing Pulmonary Embolism
| NCT ID | NCT07491094 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sahlgrenska University Hospital |
| Condition | Pulmonary Embolism (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2026-04-01 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PURPOSE The two related purposes of the RE-TyPE study are: 1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and 2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital HYPOTHESES 1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome 2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital
Eligibility Criteria
Inclusion Criteria: 1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital 2. Written informed consent Exclusion Criteria from Cohort A: 1. Low risk, intermediate-low risk or high risk PE\* 2. \>48 hours since arrival to hospital 3. Expected inability to comply with the protocol (e.g. dementia) There are no exclusion criteria from Cohort B. Patients in Cohort B who are not part of Cohort A may be included at diagnosis (day 0) or at follow-up (\~day 90). \*If biomarkers (and/or echocardiography) are not available in hemodynamically stable patients, RV/LV-ratio \>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07491094 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Embolism (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07491094 currently recruiting?
Yes, NCT07491094 is actively recruiting participants. Contact the research team at rickard.zeijlon@vgregion.se for enrollment information.
Where is the NCT07491094 trial being conducted?
This trial is being conducted at Gothenburg, Sweden, Gothenburg, Sweden, Gothenburg, Sweden.
Who is sponsoring the NCT07491094 clinical trial?
NCT07491094 is sponsored by Sahlgrenska University Hospital. The trial plans to enroll 400 participants.